OPDP Researchers To Examine Implied Claims in DTC Drug Promotion

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

OPDP Researchers To Examine Implied Claims in DTC Drug Promotion

Researchers Also Move Ahead with Survey Assessing DTC Quantitative Claims

J.W. Schomisch

December 21, 2023 at 12:27 PM EST

Researchers with the FDA’s Office of Prescription Drug Promotion (OPDP) proposed new research looking at implied claims in Direct-to-Consumer (DTC) drug promotions as well as continuing with a survey, proposed in April, to assess DTC Quantitative Claims. “Understanding how consumers who self-report having been diagnosed with a target condition interpret implied claims in DTC ... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

OPDP Researchers To Examine Implied Claims in DTC Drug Promotion

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT